JW (Cayman) Therapeutics Co (JW (Cayman) Therapeutics Co) EPS (Basic) : $-0.26 (TTM As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is JW (Cayman) Therapeutics Co EPS (Basic)?

JW (Cayman) Therapeutics Co's basic earnings per share (Basic EPS) for the six months ended in Dec. 2023 was $-0.13. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.26.

JW (Cayman) Therapeutics Co's EPS (Diluted) for the six months ended in Dec. 2023 was $-0.13. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.26.

JW (Cayman) Therapeutics Co's EPS without NRI for the six months ended in Dec. 2023 was $-0.07. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2023 was -0.20.

During the past 3 years, the average EPS without NRI Growth Rate was 52.60% per year. During the past 5 years, the average EPS without NRI Growth Rate was -20.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 6 years, JW (Cayman) Therapeutics Co's highest 3-Year average EPS without NRI Growth Rate was 52.60% per year. The lowest was -68.40% per year. And the median was -32.70% per year.

JW (Cayman) Therapeutics Co EPS (Basic) Historical Data

The historical data trend for JW (Cayman) Therapeutics Co's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

JW (Cayman) Therapeutics Co EPS (Basic) Chart

JW (Cayman) Therapeutics Co Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EPS (Basic)

Get a 7-Day Free Trial

-0.24

-1.93

-0.28

-0.30

-0.26

JW (Cayman) Therapeutics Co Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EPS (Basic)	Get a 7-Day Free Trial						-0.17	-0.16	-0.15	-0.13	-0.13

JW (Cayman) Therapeutics Co EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

JW (Cayman) Therapeutics Co's Basic EPS for the fiscal year that ended in Dec. 2023 is calculated as

Basic EPS (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-107.559	-	0)	/	411.530
	=	-0.26

JW (Cayman) Therapeutics Co's Basic EPS for the quarter that ended in Dec. 2023 is calculated as

Basic EPS (Q: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(0	-	0)	/	411.933
	=	0.00

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-0.26

JW (Cayman) Therapeutics Co (OTCPK:JWCTF) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

JW (Cayman) Therapeutics Co EPS (Basic) Related Terms

Thank you for viewing the detailed overview of JW (Cayman) Therapeutics Co's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

JW (Cayman) Therapeutics Co (JW (Cayman) Therapeutics Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » JW (Cayman) Therapeutics Co Ltd (OTCPK:JWCTF) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

02126:Hong Kong

Address

No. 699 Zhong Ke Road, 5F, Building B, Pudong New District, Shanghai, CHN

Website

https://www.jwtherapeutics.com

JW (Cayman) Therapeutics Co Ltd is a clinical-stage cell therapy company in China. It focuses on developing, manufacturing, and commercializing breakthrough cell-based immunotherapies for hematological cancers and solid tumors. Its lead product candidate is relmacabtagene autoleucel, which is a potential superior anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy intended for the treatment of a range of hematological cancers.

JW (Cayman) Therapeutics Co (JW (Cayman) Therapeutics Co) Headlines

No Headlines